Hightide Therapeutics (hong Kong) Limited

This study tested a drug called HTD1801 in 59 adults with primary sclerosing cholangitis (PSC), a rare liver disease. Participants took either a low dose, a high dose, or a placebo for 18 weeks. The main goal was to see if the drug could lower a liver enzyme called ALP, which is …

This phase 2 trial is testing whether an experimental drug called HTD1801 can reduce liver fat and improve blood sugar control in adults who have both nonalcoholic steatohepatitis (NASH) and type 2 diabetes. Participants receive either HTD1801 or a placebo for 18 weeks, and resea…

This phase 2 trial is testing an experimental drug called HTD1801 (BUDCA) in adults with primary biliary cholangitis (PBC) who haven't responded adequately to standard treatment. The goal is to see if the drug can safely lower alkaline phosphatase (ALP) levels, a key marker of li…

This trial tests an experimental oral drug called HTD1801 in adults with nonalcoholic steatohepatitis (NASH), a serious liver condition, along with liver fibrosis and type 2 diabetes or prediabetes. Participants receive either HTD1801 or a placebo to see if the drug can improve l…

This trial evaluates an experimental drug called HTD1801 in overweight or obese adults with high cholesterol. The study aims to see if the drug is safe and tolerable when taken daily at different doses, and how the body processes it. Participants are randomly assigned to receive …

This early-stage trial is testing an experimental drug called HTD4010, a synthetic version of a natural peptide that may help the pancreas regenerate insulin-producing cells. The study enrolls healthy, non-diabetic volunteers to receive single ascending doses of the drug or a pla…

This early-stage trial tests whether a single dose of HTD1801, an experimental drug for primary sclerosing cholangitis, is safe and tolerable in healthy adults. Researchers will monitor participants for side effects and measure how the drug moves through the body. The goal is to …